Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

Scientists develop new blood test to identify individuals at high risk of developing hypertrophic cardiomyopathy, most common ...

This move represented a sharp increase in price on volume nearly 3x the average daily trading volume, indicating robust ...

The FDA has approved Myqorzo for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.

Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for hypertrophic cardiomyopathy.

I was with a group of friends recently – drink had been taken, admittedly – and one of them said, “Sometimes I wish I could ...

Edgewise Therapeutics (EWTX) stock rises as the company updates mid-stage trial results for EDG-7500, its test drug for ...

The Kerala Health Minister visits Ernakulam General Hospital after a groundbreaking heart transplant was performed on Durga ...

That morning, Edgewise presented interim data from its ongoing Phase 2 clinical trial of EDG-7500, an investigational drug targeting hypertrophic cardiomyopathy (HCM). This is a genetic heart ...